Gemphire Therapeutics (GEMP)

Gemphire Therapeutics is a clinical-stage biopharmaceutical company headquartered in Michigan focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both. Gemphire licensed its lead asset, gemcabene (CI-1027), from Pfizer in 2011 and is developing it as a novel, once-daily, oral therapy, for patients with high cardiovascular and pancreatitis risk who are unable to achieve normal levels of LDL-C or triglycerides with statins or other therapies. GEMP is focused on a broad spectrum of indications for dyslipidemia patients ranging from the orphan indication of Homozygous Familial Hypercholesterolemia (HoFH) to more prevalent conditions, such as Heterozygous Familial Hypercholesterolemia (HeFH), Atherosclerotic Cardiovascular Disease (ASCVD) and Severe Hypertriglyceridemia (SHTG) as well as strategies for leveraging gemcabene’s additive LDL-C lowering characteristics and lack of drug-drug interaction with statins to pursue combination therapies, the foundation of the treatment paradigm for dyslipidemia patients.